RESUMO
OBJECTIVE: Selective decontamination of the digestive tract (SDD) is a well-studied but hotly contested medical intervention of enhanced infection control. Here, we aim to characterise the changes to the microbiome and antimicrobial resistance (AMR) gene profiles in critically ill children treated with SDD-enhanced infection control compared with conventional infection control. DESIGN: We conducted shotgun metagenomic microbiome and resistome analysis on serial oropharyngeal and faecal samples collected from critically ill, mechanically ventilated patients in a pilot multicentre cluster randomised trial of SDD. The microbiome and AMR profiles were compared for longitudinal and intergroup changes. Of consented patients, faecal microbiome baseline samples were obtained in 89 critically ill children. Additionally, samples collected during and after critical illness were collected in 17 children treated with SDD-enhanced infection control and 19 children who received standard care. RESULTS: SDD affected the alpha and beta diversity of critically ill children to a greater degree than standard care. At cessation of treatment, the microbiome of SDD patients was dominated by Actinomycetota, specifically Bifidobacterium, at the end of mechanical ventilation. Altered gut microbiota was evident in a subset of SDD-treated children who returned late longitudinal samples compared with children receiving standard care. Clinically relevant AMR gene burden was unaffected by the administration of SDD-enhanced infection control compared with standard care. SDD did not affect the composition of the oral microbiome compared with standard treatment. CONCLUSION: Short interventions of SDD caused a shift in the microbiome but not of the AMR gene pool in critically ill children at the end mechanical ventilation, compared with standard antimicrobial therapy.
Assuntos
Estado Terminal , Descontaminação , Fezes , Humanos , Projetos Piloto , Estado Terminal/terapia , Masculino , Feminino , Pré-Escolar , Fezes/microbiologia , Descontaminação/métodos , Criança , Microbioma Gastrointestinal/efeitos dos fármacos , Controle de Infecções/métodos , Respiração Artificial , Lactente , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Farmacorresistência Bacteriana/genética , Trato Gastrointestinal/microbiologia , Orofaringe/microbiologiaRESUMO
OBJECTIVES: Management of hypotension is a fundamental part of pediatric critical care, with cardiovascular support in the form of fluids or vasoactive drugs offered to every hypotensive child. However, optimal blood pressure (BP) targets are unknown. The PRotocolised Evaluation of PermiSSive BP Targets Versus Usual CaRE (PRESSURE) trial aims to evaluate the clinical and cost-effectiveness of a permissive mean arterial pressure (MAP) target of greater than a fifth centile for age compared with usual care. DESIGN: Pragmatic, open, multicenter, parallel-group randomized control trial (RCT) with integrated economic evaluation. SETTING: Eighteen PICUs across the United Kingdom. PATIENTS: Infants and children older than 37 weeks corrected gestational age to 16 years accepted to a participating PICU, on mechanical ventilation and receiving vasoactive drugs for hypotension. INTERVENTIONS: Adjustment of hemodynamic support to achieve a permissive MAP target greater than fifth centile for age during invasive mechanical ventilation. MEASUREMENTS AND MAIN RESULTS: Randomization is 1:1 to a permissive MAP target or usual care, stratified by site and age group. Due to the emergency nature of the treatment, approaching patients for written informed consent will be deferred until after randomization. The primary clinical outcome is a composite of death and days of ventilatory support at 30 days. Baseline demographics and clinical status will be recorded as well as daily measures of BP and organ support, and discharge outcomes. This RCT received Health Research Authority approval (reference 289545), and a favorable ethical opinion from the East of England-Cambridge South Research Ethics Committee on May 10, 2021 (reference number 21/EE/0084). The trial is registered and has an International Standard RCT Number (reference 20609635). CONCLUSIONS: Trial findings will be disseminated in U.K. national and international conferences and in peer-reviewed journals.
Assuntos
Estado Terminal , Hipotensão , Unidades de Terapia Intensiva Pediátrica , Respiração Artificial , Humanos , Hipotensão/terapia , Criança , Lactente , Estado Terminal/terapia , Pré-Escolar , Adolescente , Respiração Artificial/métodos , Reino Unido , Análise Custo-Benefício , Ensaios Clínicos Pragmáticos como Assunto , Pressão Sanguínea/efeitos dos fármacos , Recém-Nascido , Cuidados Críticos/métodos , Vasoconstritores/uso terapêuticoRESUMO
Importance: The ways in which we access, acquire, and use data in clinical trials have evolved very little over time, resulting in a fragmented and inefficient system that limits the amount and quality of evidence that can be generated. Observations: Clinical trial design has advanced steadily over several decades. Yet the infrastructure for clinical trial data collection remains expensive and labor intensive and limits the amount of evidence that can be collected to inform whether and how interventions work for different patient populations. Meanwhile, there is increasing demand for evidence from randomized clinical trials to inform regulatory decisions, payment decisions, and clinical care. Although substantial public and industry investment in advancing electronic health record interoperability, data standardization, and the technology systems used for data capture have resulted in significant progress on various aspects of data generation, there is now a need to combine the results of these efforts and apply them more directly to the clinical trial data infrastructure. Conclusions and Relevance: We describe a vision for a modernized infrastructure that is centered around 2 related concepts. First, allowing the collection and rigorous evaluation of multiple data sources and types and, second, enabling the possibility to reuse health data for multiple purposes. We address the need for multidisciplinary collaboration and suggest ways to measure progress toward this goal.
RESUMO
Background: Severe pneumonia in African children results in poor long-term outcomes (deaths/readmissions) with undernutrition as a key risk factor. We hypothesised additional energy/protein-rich Ready-to-Use Therapeutic Foods (RUTF) would meet additional nutritional requirements and improve outcomes. Methods: COAST-Nutrition was an open-label Phase 2 randomised controlled trial in children (aged 6 months-12 years) hospitalised with severe pneumonia (and hypoxaemia, SpO2 <92%) in Mbale, Soroti, Jinja, Masaka Regional Referral Hospitals, Uganda and Kilifi County Hospital, Kenya (ISRCTN10829073 (registered 6th June 2018) PACTR202106635355751 (registered 2nd June 2021)). Children were randomised (ratio 1:1) to enhanced nutritional supplementation with RUTF (plus usual diet) for 56 days vs usual diet (control). The primary outcome was change in mid-upper arm circumference (MUAC) at 90 days as a composite with mortality. Secondary outcomes include anthropometric status, mortality, and readmissions at Days 28, 90 and 180. Findings: Between 12 August 2018 and 22 April 2022, 846 eligible children were randomised, 424 to RUTF and 422 to usual diet, and followed for 180-days [12 (1%) lost-to-follow-up]. RUTF supplement was initiated in 417/419 (>99%). By Day 90, there was no significant difference in the composite endpoint (probabilistic index 0.49, 95% CI 0.45-0.53, p = 0.74). Respective 90-day mortality (13/420 3.1% vs 14/421 3.3%) and MUAC increment (0.54 (SD 0.85) vs 0.55 (SD 0.81)) were similar between arms. There was no difference in any anthropometric secondary endpoints to Day 28, 90 or 180 except skinfold thickness at Day 28 and Day 90 was greater in the RUTF arm. Serious adverse events were higher in the RUTF arm (n = 164 vs 108), mainly due to hospital readmission for acute illness (54/387 (14%) vs 37/375 (10%). Interpretation: Our study suggested that nutritional supplementation with RUTF did not improve outcomes to 180 days in children with severe pneumonia. Funding: This trial is part of the EDCTP2 programme (grant number RIA-2016S-1636-COAST-Nutrition) supported by the European Union, and UK Joint Global Health Trials scheme: Medical Research Council, Department for International Development, Wellcome Trust (grant number MR/L004364/1, UK).
RESUMO
Objetivos: describir la estructura de las Unidades de Cuidado Intensivo (UCIs) en Colombia en términos de los recursos humano y tecnológico, para los sectores público y privado; comparar los resultados contra estándares colombianos; e investigar los factores asociados con las tasas de rechazo para ingreso. Diseño: encuesta nacional en UCIs durante 1996-1997, con una comparación concurrente con la resolución 4252 de 1997, que establece los estándares para la disposición del cuidado intensivo en Colombia. Lugar: UCIs para adultos, tanto médicas como quirúrgicas, dentro de hospitales en Colombia. Mediciones y resultados principales: se identificaron 89 UCIs colombianas mediante diferentes criterios. La tasa de respuesta de la encuesta fue 71 por ciento (63/89). En general, 41 por ciento fueron UCIs en hospitales del sector público (comparado con los privados). Durante 1996-1997, comparado con UCIs en hospitales privados, aquellos en los hospitales públicos tuvieron estancia promedio en UCI más larga (seis vs. cuatro días, P=0.05), las estancias más largas en UCI (44 vs. 30 días, P=0.04), admitieron menos pacientes por mes (27 vs. 30 pacientes, P=0.02) y tuvieron menores giro-cama (3.14 vs. 4.2, P=0.03). Cuarenta y dos por ciento de las UCIs en hospitales públicos reportaron rechazo de pacientes que necesitaban cuidados en UCI entre una a diez veces por semana, contra solo 14 por ciento en las UCIs privadas (P=0.0049). La no disponibilidad de camas fue la causa más frecuente de rechazo, por encima del 85 por ciento de las UCIs en los dos sectores. Cuando se comparan con los estándares colombianos, tanto el sector público como el privado tienen relaciones enfermera a paciente bajas, y escasez de recursos tecnológicos (principalmente ventiladores mecánicos). Conclusiones: los recursos para los servicios de cuidado intensivo en Colombia se encuentran por debajo de los estándares nacionales esperados. Se necesitará una inversión grande de fondos sociales para aumentar los recursos actuales hasta los esperados, especialmente en el sector público. Estos resultados proveerán las bases para la búsqueda de soluciones concertadas entre el Ministerio de Salud de Colombia, las instituciones prestadoras de servicios de salud, y la sociedad de Medicina Crítica y Cuidado Intensivo.